María Díez Campelo
0000-0002-1467-6779
12 papers found
Refreshing results…
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
Missing publications? Search for publications with a matching author name.